Table 3. Clinical parameters in CF patients with normal and pathological u-OC percentage.
| u-OC [%] | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Parameters Median (1st–3rd quartile) | <20 | 20–50 | ≥50 | p | Parameters (N%) | <20 | 20–50 | ≥50 | p | |
| Age [years] | 12.1 (6.6–18.0) | 19.1 (7.5–27.7) | 14.7 (8.2–19.9) | 0.0673 | Age [years] | <18 | 78 (66.7) | 10 (8.5) | 29 (24.8) | 0.0153 |
| ≥18 | 26 (55.3) | 12 (25.5) | 9 (19.2) | |||||||
| Body weight (Z-score) | −1.07 (−1.74– 0.42) | −1.33 (−1.86– −0.52) | −0.92 (−1.80– 0.40) | 0.9044 | Body weight (Z-score) | <−1 | 53 (64.6) | 12 (14.6) | 17 (20.8) | 0.7216 |
| >−1 | 51 (62.2) | 10 (12.2) | 21 (25.6) | |||||||
| Body height (Z-score) | −0.86 (−1.78– −0.22) | −0.47 (−2.08–0.13) | −0.74 (−2.10–0.09) | 0.5186 | Body height (Z-score) | <−1 | 45 (62.5) | 10 (13.9) | 17 (23.6) | 0.9999 |
| >−1 | 59 (64.1) | 12 (13.0) | 21 (22.9) | |||||||
| FEV1 [%] | 72.6 (36.4–90.2) | 40.2 (23.0–67.5) | 58.0 (31.3–81.7) | 0.0663 | FEV1 [%] | <80% | 51 (60.7) | 14 (16.7) | 19 (22.6) | 0.2595 |
| >80% | 29 (64.4) | 3 (6.7) | 13 (28.9) | |||||||
| Albumin [g/dl] | 3.87 (3.57–4.16) | 3.81 (3.54–4.26) | 3.90 (3.59–4.26) | 0.3829 | Albumin [g/dl] | <3.5 | 20 (71.4) | 3 (10.7) | 5 (17.9) | 0.6250 |
| ≥3.5 | 84 (61.8) | 19 (14.0) | 33 (24.2) | |||||||
| ALT [U/l] | 23.5 (17.0–31.0) | 27.5 (18.0–43.5) | 24.0 (20.0–37.0) | 0.4220 | CFTR gene mutation | F508del/F508del | 45 (63.4) | 8 (11.3) | 18 (25.3) | 0.6974 |
| other/other | 59 (63.4) | 14 (15.1) | 20 (21.5) | |||||||
| s/s1 | 70 (68.0) | 11 (10.7) | 22 (21.3) | 0.2235 | ||||||
| other/other | 34 (55.7) | 11 (18.0) | 16 (26.3) | |||||||
| AST [U/l] | 28.0 (22.0–38.2) | 33.0 (18.2–44.8) | 28.0 (21.0–38.0) | 0.9455 | Liver diseases | Cirrhosis | 5 (55.6) | 1 (11.1) | 3 (33.3) | 0.6814 |
| Other liver involvement | 30 (65.2) | 8 (17.4) | 8 (17.4) | |||||||
| No | 69 (63.3) | 13 (11.9) | 27 (24.8) | |||||||
| GGT [U/l] | 13.0 (10.0–22.5) | 20.0 (11.2–27.2) | 19.0 (11.0–34.0) | 0.1832 | Diabetes | Yes | 12 (66.7) | 5 (27.8) | 1 (5.5) | 0.0502 |
| No | 92 (63.0) | 17 (11.6) | 37 (25.4) | |||||||
| Ps. aeruginosa colonization | Yes | 58 (60.4) | 16 (16.7) | 22 (22.9) | 0.3346 | |||||
| No | 46 (67.6) | 6 (8.8) | 16 (23.6) | |||||||
| INR | 1.08 (1.01–1.15) | 1.08 (0.98–1.15) | 1.10 (1.01–1.16) | 0.0943 | Pancreatic sufficiency | Yes | 12 (50.0) | 5 (20.8) | 7 (29.2) | 0.2527 |
| No | 92 (65.7) | 17 (12.1) | 31 (22.2) | |||||||
| Permanent inhaled antibiotics | Yes | 29 (69.0) | 5 (11.9) | 8 (19.1) | 0.7278 | |||||
| No | 75 (61.5) | 17 (13.9) | 30 (24.6) | |||||||
| Enzyme dose [FIP/kg/day] | 3698 (26656–5825) | 2801 (1215–5162) | 3309 (1773–5162) | 0.2913 | Permanent oral antibiotics | Yes | 29 (64.4) | 5 (11.1) | 11 (24.5) | 0.9338 |
| No | 75 (63.0) | 17 (14.3) | 27 (22.7) | |||||||
| Intravenous antibiotics (in last 3 months) | Yes | 64 (64.6) | 17 (17.2) | 18 (18.2) | 0.0728 | |||||
| No | 40 (61.5) | 5 (7.7) | 20 (30.8) | |||||||
| Vitamin K dose [mg/kg/week] | 0.41 (0.25–0.61) | 0.28 (0.19–0.49) | 0.14 (0–0.37) | 0.00012 | Oral antibiotics (in last 3 months) | Yes | 20 (69.0) | 4 (13.8) | 5 (17.2) | 0.7235 |
| No | 84 (62.2) | 18 (13.3) | 33 (24.5) | |||||||
| Inhaled glucocorticoid therapy | Yes | 53 (68.8) | 9 (11.7) | 15 (19.5) | 0.3965 | |||||
| No | 51 (58.6) | 13 (14.9) | 23 (26.5) | |||||||
| Vitamin K dose [mg/week] | 12.0 (5.6–20.0) | 10.0 (5.0–20.0) | 6.7 (0–17.5) | 0.00362 | Vitamin K supplementation | <2.1 mg/week3 | 5 (23.8) | 3 (14.3) | 13 (61.9) | <0.0001 |
| >2.1 mg/week | 99 (69.2) | 19 (13.3) | 25 (17.5) | |||||||
1Severe class of mutations on both alleles of the CFTR gene
2u-OC < 20% vs 20–50% n.s; u-OC < 20 vs. >50% p < 0.05; u-OC 20–50% vs >50% n.s.
3Patients not receiving vitamin K or receiving less than the recommended dosage for CF (0.3 mg/d).